Table 3.
Genotypic frequencies of SNPs and their respective average weekly dose (n = 279)
| Polymorphism (MAF,%) | CYP2C9*2 (13.4) and CYP2C9*3 (5.4) | VKORC1 −1639G>A (36.7) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype | CYP2C9*1/*1 | CYP2C9*1/*2 | CYP2C9*1/*3 | CYP2C9*2/*2 | CYP2C9*2/*3 | CYP2C9*3/*3 | −1639GG | −1639GA | −1639AA |
| Frequencies (%) | 182 (65.2) | 64 (22.9) | 25 (9.0) | 3 (1.1) | 5 (1.8) | 0 (0) | 112 (40.2) | 129 (46.2) | 38 (13.6) |
| Weekly dose (mg) | 36.72 | 28.98 | 27.30 | 15.00 | 17.50 | - | 41.38 | 29.57 | 23.75 |
| P (anova) | <0.001 | <0.001 | |||||||
| Polymorphism (MAF,%) | VKORC1 1173C>T (36.9) | VKORC1 3730G>A (39.8) | CYP4F2 1347C>T (32.4) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype | 1173CC | 1173CT | 1173TT | 3730GG | 3730GA | 3730AA | CC | CT | TT |
| Frequencies (%) | 112 (40.1) | 128 (45.9) | 39 (14.0) | 106 (38.0) | 124 (44.4) | 49 (17.6) | 119 (42.7) | 139 (49.8) | 21 (7.5) |
| Weekly dose (mg) | 41.36 | 29.86 | 23.01 | 29.10 | 33.63 | 42.81 | 31.53 | 34.93 | 35.48 |
| P (anova) | <0.001 | <0.001 | 0.084 | ||||||
| Polymorphism (MAF,%) | Factor 2 494C>T (15.6) | VKORC1 diplotypes [−1639/1173/3730]† | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Genotype | 494CC | 494CT | 494TT | GCG/GCG | GCG/GCA | GCG/ATG | GCA/GCA | GCA/ATG | ATG/ATG |
| Frequencies (%) | 198 (71.0) | 75 (26.9) | 6 (2.1) | 20 (7.2) | 40 (14.3) | 46 (16.5) | 47 (16.8) | 79 (28.3) | 37 (13.3) |
| Weekly dose (mg) | 33.51 | 33.80 | 30.42 | 41.13 | 40.75 | 28.75 | 42.50 | 30.19 | 23.44 |
| P (anova) | 0.807 | <0.001 | |||||||
MAF, minor allele frequency.
†
Only the main diplotypes, which account for 96.4% of diplotypes.